ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQB:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce a US$450,000 investment in Wuhan General Group (China) Inc. (OTC PINK:WUHN) (“Wuhan”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research.
The Company will acquire 1,500,000 units (the “Units”) at a price of US$0.30 per Unit. Each Unit will consist of one (1) common share of Wuhan (a “Common Share”) and one Common Share purchase warrant (a “Warrant”) exercisable at US$0.30 per Warrant. The Warrants will expire three (3) years from the date of issuance. The closing date for the private placement will be at the latest on January 31, 2021.
Sheldon Inwentash, Chairman and CEO of ThreeD Capital stated, “The investment thesis of ThreeD Capital is that psychedelics are going to experience a paradigm shifting and parabolic growth stage over this decade, leading to a critical role in the treatment of anxiety, depression, addiction and other mental health issues that traditional pharmaceuticals have not been able to adequately solve. Though we have made other smaller investments in the space, our investment in Wuhan General Group (China) represents our largest investment to date in a psychedelics company. We are investing in Wuhan General Group (China) because of the deep expertise and scientific knowledge this company has in psychedelics.”
This Press Release is available on the ThreeD Capital verified forum on AGORACOM. The forum is live and can be found at https://agoracom.com/ir/threedcapital/forums/discussion
About Wuhan General Group (China) Inc.
Wuhan General Group (China) Inc., through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
About ThreeD Capital Inc.
ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors. ThreeD’s investment strategy is to invest in multiple private and public companies across a variety of sectors globally. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services and access to the Company’s ecosystem.
| For further information: |
| Gerry Feldman, CPA, CA |
| Chief Financial Officer and Corporate Secretary [email protected] |
| Phone: 416-941-8900 ext 106 |
Tags: artificial intelligence, blockchain, CSE, Digital, Disruptive companies, disruptive technologies, esports, gold, IOT, shrooms, small cap, small cap stocks